Although oncology is unique among disciplines in its personalisation, being markedly influenced by somatic mutations, it is expected to be in the vanguard of developments under this initiative.
Given that these tests aim to infer a complex genome-wide relationship between average mutational effects and the form of epistasis from a small sample of mutations, it is encouraging to find such a strong trend.
While the epitopes derived from sequentially conserved regions may undergo mutations, it is worthwhile to explore the structurally conserved regions as a new dimension for epitope prediction.
Although this may lead to mutations, it is preferable to a complete halt in DNA replication, which leads to cell death.
Regardless of the mechanism underlying the effect of the mutations, it is important for screening approaches that they do not have a major influence on transport kinetics and inhibition.
To develop hepatitis C virus (HCV) direct-acting antiviral (DAA) drugs that can treat most HCV genotypes and offer higher barriers for treatment-resistant mutations, it is important to study resistance-associated variants (RAVs).
Therefore, at least with random mutations, it is more common to lose exons and gain introns.
As human immunodeficiency virus type 1 (HIV-1) resistance to azidothymidine (AZT) requires selection of sequential mutations, it is a good system to study the impact of epistasis.
It is important to note that although the diversity observed in the described strains seems to have originated from point mutations, it is impossible to dismiss the impact of recombination in the generation of genetic diversity.
For such detailed characterisation and identification of causative mutations, it is important to define the natural genetic variation within field populations of An. funestus rather than rely on a laboratory strain.
However, as gBGC does not induce mutations, it is not expected to strongly influence the number of WS polymorphisms.
